CELCUITY INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.76 USD | -5.10% |
|
-0.42% | +15.03% |
| May. 16 | Craig-Hallum Adjusts Price Target on Celcuity to $27 From $25, Assumes Buy Rating | MT |
| May. 16 | Celcuity Q1 Net Loss Widens; Shares Rise After Hours | MT |
Presentation Operator MessageOperator (Operator)Good afternoon, and welcome to Celcuity's Seco...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small molecule reversible inhibitor, that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic target of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its initial clinical development programs for gedatolisib are focusing on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. Its VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells to identify new groups of cancer patients.
Calendar
2024-08-07
- Q2 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
17.66
USD
Average target price
28.96
USD
Spread / Average Target
+64.01%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +15.03% | 552M | |
| +9.42% | 114B | |
| +11.84% | 104B | |
| -14.15% | 22.41B | |
| -1.05% | 22.28B | |
| -5.29% | 19.07B | |
| -38.29% | 18B | |
| -4.16% | 17.89B | |
| +7.99% | 14.28B | |
| +36.24% | 12.55B |
- Stock Market
- Equities
- CELC Stock
- News Celcuity Inc.
- Transcript : Celcuity Inc., Q2 2022 Earnings Call, Aug 11, 2022
